

**PRODUCT INFORMATION**

<b>Clone ID</b>	1A12
<b>Target</b>	Dxd
<b>Synonyms</b>	N.A.
<b>Host Species</b>	Rabbit
<b>Description</b>	Anti-Dxd antibody(1A12); Rabbit mAb
<b>Delivery</b>	In Stock
<b>Uniprot ID</b>	N.A.
<b>IgG type</b>	Rabbit IgG
<b>Clonality</b>	Monoclonal
<b>Reactivity</b>	N.A.
<b>Applications</b>	ELISA
<b>Recommended Dilutions</b>	ELISA 1:5000-10000
<b>Purification</b>	Purified from cell culture supernatant by affinity chromatography
<b>Endotoxin</b>	Less than 1.0 EU/ $\mu$ g by the LAL method. For <1 EU/mg requirements, please contact us for customization.
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Storage&amp;Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Sterility</b>	Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 $\mu$ m) prior to use.
<b>Background</b>	Dxd is a potent anti-cancer drug, acting as an alkaloid camptothecin analog and a DNA topoisomerase I inhibitor. It forms a stable complex with topoisomerase I and DNA, impeding DNA replication and inducing cancer cell death. Dxd is utilized as a payload in specific antibody-drug conjugates (ADCs), with examples such as trastuzumab deruxtecan targeting HER2 and patritumab deruxtecan targeting HER3.
<b>Usage</b>	Research use only
<b>Conjugate</b>	Unconjugated
<b>DIMA Disclaimer</b>	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scr



### ELISA assay to evaluate Anti-Dxd Antibody 0.2µg Human IgG-Dxd per well




Figure1. Elisa plates were pre-coated with IgG-Dxd (0.2µg/per well). Serial diluted anti-Dxd monoclonal antibody (DME101026) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-Dxd monoclonal antibody binding with IgG-Dxd is 3.690ng/ml.

